A randomized controlled trial is conducted to evaluate the efficacy and safety of a novel P2Y12 inhibitor added to aspirin, compared to aspirin alone, in patients with a recent transient ischemic attack (TIA) or minor ischemic stroke. The primary efficacy endpoint is the 1-year incidence of recurrent stroke, and the primary safety endpoint is the 1-year incidence of major bleeding.
The 1-year event rates in the aspirin-alone (control) group were:
- Recurrent stroke:
- Major bleeding:
In the group receiving the novel P2Y12 inhibitor plus aspirin, the relative risk reduction (RRR) for recurrent stroke was compared to the control group. However, this intervention group also had a relative risk (RR) of for major bleeding compared to the control group.
Based on these results, what is the number needed to harm (NNH) for major bleeding? (Enter the exact integer).
Cevap: 40 patients